

# Pfizer Breakfast Talk: From idea to patient

From a brilliant idea, lab tests and clinical trials to the first prescription.  
The care that precedes the cure.

When: Wednesday February 13th 2019, 08:30 – 09:30, breakfast available from 08:00.

Where: Gamla Gästmatsalen, Restaurant Inspira, Medicon Village Lund

Register to: [magnus.e.johansson@pfizer.com](mailto:magnus.e.johansson@pfizer.com) - No later than February 6th

## AGENDA

- Pfizer Sweden: Marketing, Manufacturing and Science/Collaboration  
Christoph Varenhorst, Country Medical Director
- Clinical Research  
Karolina Rask, Director Clinical Site Management, Scandinavia/Baltics
- Ongoing collaborations  
Anders Mälarstig, Director Human Genetics

### **Christoph Varenhorst**

Country Medical Director of Pfizer Sweden and associate professor of medicine. In his role at Pfizer, he provides the leadership to all in-country medical functions and is the country senior medical voice internally and externally.

### **Karolina Rask**

Director Clinical Site Management, Scandinavia/Baltics, Molecular biologist with global experience from clinical research and work in both biotech and pharma. Responsible for Pfizer's clinical studies run in the Nordic and Baltic region.

### **Anders Mälarstig**

Anders Mälarstig is a Director of Human Genetics in the Target Sciences and Technologies unit at Pfizer R&D. The unit focuses on early target discovery and validation with strong human confidence in rationale. Anders is embedded at the Karolinska Institute to lead external collaborations at KI, in the Nordics and UK.

